Mukesh Ambani’s group is getting into genetic mapping, following the trend created by US startups like 23andMe. At US$145, the test will be more affordable than currently available options in India’s growing consumer market.
Strand Life Sciences developed the product; and in 2021, Reliance Industries acquired about 80% of the Bengaluru-based firm.
The genome test, which is about 86% cheaper than other offerings available locally, can reveal a person’s predisposition to cancers, cardiac and neuro-degenerative ailments as well as identify inherited genetic disorders, he said.
